跳至主要内容
临床试验/NCT01551056
NCT01551056已完成3 期

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of Cetirizine 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

Aciex Therapeutics, Inc.1 个研究点 分布在 1 个国家目标入组 91 人开始时间: 2012年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
91
试验地点
1
主要终点
Ocular Itching at Duration of Action (16 Hours + 1 Hour Post-dose)

研究概览

简要总结

The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
10 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • positive bilateral conjunctival allergen challenge (CAC) reaction

排除标准

  • known contraindications or sensitivities to the study medication or its components
  • any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters
  • use of disallowed medication during the period indicated prior to the enrollment or during the study

研究组 & 干预措施

AC-170 0.24%

Experimental

干预措施: AC-170 0.24% (Drug)

AC-170 0%

Placebo Comparator

干预措施: AC-170 0% (Drug)

结局指标

主要结局

Ocular Itching at Duration of Action (16 Hours + 1 Hour Post-dose)

时间窗: 3, 5, 7 minutes post-CAC

A treatment efficacy Conjunctival Allergen Challenge (CAC) was performed 16 hours + 1 hour after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

Conjunctival Redness at Duration of Action (16 Hours + 1 Hour Post-dose)

时间窗: 7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Conjunctival Redness at Onset of Action (15 Minutes Post-dose)

时间窗: 7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Ocular Itching at Onset of Action (15 Minutes Post-dose)

时间窗: 3, 5, 7 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

次要结局

  • Nasal Congestion at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Ciliary Redness at Duration of Action (16 Hours + 1 Hour Post-dose)(7, 15, 20 minutes post-CAC)
  • Episcleral Redness at Duration of Action (16 Hours + 1 Hour Post-dose)(7, 15, 20 minutes post-CAC)
  • Eyelid Swelling at Duration of Action (16 Hours + 1 Hour Post-dose)(7, 15, 20 minutes post-CAC)
  • Eyelid Swelling at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Duration of Action (16 Hours + 1 Hour Post-dose)(7, 15, 20 minutes post-CAC)
  • Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Chemosis at Duration of Action (16 Hours + 1 Hour Post-dose)(7, 15, 20 minutes post-CAC)
  • Rhinorrhea at Duration of Action (16 Hours +1 Hour Post-dose)(7, 15, 20 minutes post-CAC)
  • Ear or Palate Pruritis at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Ciliary Redness at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Rhinorrhea at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Pruritis at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Congestion at Duration of Action (16 Hours + 1 Hour Post-dose)(7, 15, 20 minutes post-CAC)
  • Tolerability of Study Medication at Visit 3A(upon instillation, 1 minute and 2 minutes post instillation)
  • Episcleral Redness at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Chemosis at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Tearing at Duration of Action (16 Hours + 1 Hour Post-dose)(7, 15, 20 minutes post-CAC)
  • Tearing at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)(7, 15, 20 minutes post-CAC)
  • Ear or Palate Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)(7, 15, 20 minutes post-CAC)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验